Literature DB >> 1544785

Color Doppler ultrasound of orbital and optic nerve blood flow: effects of posture and timolol 0.5%.

G M Baxter1, T H Williamson, G McKillop, G N Dutton.   

Abstract

Color Doppler ultrasound allows simultaneous imaging with real-time ultrasound and superimposed color-coded vascular flow, allowing visualization of vessels previously beyond the resolution of conventional imaging, such as those in the orbit. With this technique, 20 healthy volunteers were studied. Three regional vessels named 1, 2, and 3 were identified. No significant difference in maximum or minimum blood velocity or resistive index was detected between vessels 1 and 2, although significant differences were noted between both these vessels and vessel 3 (P less than 0.01 and P less than 0.001, respectively). These regional variations are unaffected by small but significant rises in pulse (P less than 0.05) and diastolic blood pressure (P less than 0.01) induced by postural change. No significant change within each vessel was recorded in response to posture, reflecting autoregulation within these vessels. Using a similar technique, 10 healthy volunteers were studied at baseline and at 2 hr and 3 d following the unilateral instillation of 0.5% timolol eye drops. A fall in resistive index was recorded in vessel 3 for both eyes (P less than 0.05, timolol administered eye; P less than 0.01 timolol-free eye). This effect was independent of any simultaneous fall in intraocular pressure that occurred only in the eye receiving timolol drops (P less than 0.01). These results support the presence of B receptors in the vessels at the optic nerve head (vessel 3). A fall in resistive index should not compromise the blood supply in this region, and may even increase it.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1544785

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  15 in total

1.  Color Doppler imaging identifies four syndromes of the retrobulbar circulation in patients with amaurosis fugax and central retinal artery occlusions.

Authors:  R C Sergott; P M Flaharty; W E Lieb; A C Ho; M D Kay; R A Mittra; P J Savino; T M Bosley
Journal:  Trans Am Ophthalmol Soc       Date:  1992

2.  Ocular haemodynamics in glaucoma associated with high myopia.

Authors:  F Galassi; A Sodi; F Ucci; A Harris; H S Chung
Journal:  Int Ophthalmol       Date:  1998       Impact factor: 2.031

Review 3.  Ocular blood flow measurement.

Authors:  T H Williamson; A Harris
Journal:  Br J Ophthalmol       Date:  1994-12       Impact factor: 4.638

4.  Understanding of the retinal circulation provided by an anomalous retinal vein.

Authors:  T H Williamson; D B Barr; G M Baxter
Journal:  Br J Ophthalmol       Date:  1994-10       Impact factor: 4.638

5.  What is the use of ocular blood flow measurement?

Authors:  T H Williamson
Journal:  Br J Ophthalmol       Date:  1994-05       Impact factor: 4.638

6.  Acquired color vision loss and a possible mechanism of ganglion cell death in glaucoma.

Authors:  T M Nork
Journal:  Trans Am Ophthalmol Soc       Date:  2000

7.  A comparative study on the effects of apraclonidine and timolol on the ophthalmic blood flow velocity waveforms.

Authors:  S Oruç; E C Sener
Journal:  Int Ophthalmol       Date:  1999       Impact factor: 2.031

8.  Comparison of flow velocity of ophthalmic artery between primary open angle glaucoma and normal tension glaucoma.

Authors:  Y Yamazaki; F Hayamizu
Journal:  Br J Ophthalmol       Date:  1995-08       Impact factor: 4.638

9.  Colour Doppler ultrasound in the management of a case of cranial arteritis.

Authors:  T H Williamson; G Baxter; R Paul; G N Dutton
Journal:  Br J Ophthalmol       Date:  1992-11       Impact factor: 4.638

10.  A comparison of colour Doppler imaging of orbital vessels and other methods of blood flow assessment.

Authors:  T H Williamson; G M Baxter; A Pyott; W Wykes; G N Dutton
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1995-02       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.